{"schema_version":"secwatch.filing_event.v1","accession":"0001171843-25-001410","form_type":"8-K","ticker":"APTOF","cik":"0000882361","company_name":"Aptose Biosciences Inc.","filed_at":"2025-03-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:06.652064+00:00","generated_at":"2026-05-24T22:57:32.594444+00:00","sec_items":["9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Aptose provides TUS+VEN+AZA triplet clinical update and 2025 milestones","bullets":["40mg TUS+VEN+AZA triplet achieved CRs in FLT3-WT and TP53-mutated newly diagnosed AML; no DLTs.","80mg TUS dose cohort in TUS+VEN+AZA triplet is currently enrolling.","Hanmi collaboration expected Q2 2025; $10M advance converting to common stock.","Raised approx. $37M in 2024; capital structure: 2.14M shares O/S, 1.27M warrants.","Planned data releases at EHA 2025 and ASH 2025; dose selection for Ph2/3 pivotal."],"urls":{"canonical":"https://secwatch.observer/filing/0001171843-25-001410","json":"https://secwatch.observer/filing/0001171843-25-001410.json","markdown":"https://secwatch.observer/filing/0001171843-25-001410.md","text":"https://secwatch.observer/filing/0001171843-25-001410.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/882361/000117184325001410/0001171843-25-001410-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/882361/000117184325001410/f8k_031125.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T22:57:32.594444+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}